CFH与ARMS2基因多态性不能预测年龄相关性黄斑变性患者对抗氧化剂和锌的反应:对年龄相关性眼病研究数据的独立统计评估
三个独立统计团队重新分析年龄相关性眼病研究(AREDS)数据,评估CFH与ARMS2基因型是否预测抗氧化剂和锌的疗效。研究发现支持基因-治疗交互作用的原始数据存在错误,校正多重检验后无法重复任何基因-治疗交互作用,独立数据检验亦为阴性。结论认为符合补充剂标准的患者应接受锌和抗氧化剂治疗,无需考虑基因型。
要点
- 支持基因-治疗交互作用的原始数据存在错误,校正多重检验后无法重复任何交互作用。
- 在高风险患者中观察到更多获益证据,但未发现基因型预测治疗反应。
- 符合补充剂标准的年龄相关性黄斑变性患者应接受锌和抗氧化剂治疗,无需考虑基因型。
核心结论
- 符合补充剂预防年龄相关性黄斑变性进展标准的患者应接受锌和抗氧化剂治疗,无需考虑基因型。
研究设计与样本
- 三个独立统计团队分别重新分析年龄相关性眼病研究(AREDS)数据,数据由AREDS研究者及支持基因分型的研究者分别提供。
- 关注人群为年龄相关性黄斑变性病情重于1级且有基因分型数据的AREDS参与者。
- 两组数据在测量指标上不完全重叠,最大共同集为879名参与者,两组均测量了相同的CFH和ARMS2单核苷酸多态性。
主要发现
- 发现用于支持基因-治疗交互作用初始声明数据存在错误。
- 发现高风险患者有更多获益的证据,但校正多重检验后无法重复任何基因-治疗交互作用。
- 在一个独立数据集上检验了一项基因型声明,结果为阴性。
- 即使假设交互作用确实存在,也未发现证据支持补充剂在某些基因型亚组中导致晚期年龄相关性黄斑变性风险大幅增加的声明。
临床怎么用
- 作者结论认为,符合补充剂预防年龄相关性黄斑变性进展标准的患者应接受锌和抗氧化剂治疗,无需考虑基因型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Considerable controversy has erupted in recent years regarding whether genotyping should be part of standard care for patients with age-related macular degeneration (AMD) who are being considered for treatment with antioxidants and zinc. We aimed to determine whether genotype predicts response to supplements in AMD. DESIGN: Three separate statistical teams reanalyzed data derived from the Age-Related Eye Disease Study (AREDS), receiving data prepared by the AREDS investigators and, separately, data from investigators reporting findings that support the use of genotyping. PARTICIPANTS: The population of interest was AREDS participants with AMD worse than category 1 and genotyping data available. Data from the 2 groups overlap imperfectly with respect to measurements made: the largest common set involved 879 participants for whom the same CFH and ARMS2 single nucleotide polymorphisms were measured by both groups. METHODS: Each team took a separate but complementary approach. One team focused on data concordance between conflicting studies. A second team focused on replicating the key claim of an interaction between genotype and treatment. The third team took a blank slate approach in attempting to find baseline predictors of treatment response. MAIN OUTCOME MEASURES: Progression to advanced AMD. RESULTS: We found errors in the data used to support the initial claim of genotype-treatment interaction. Although we found evidence that high-risk patients had more to gain from treatment, we were unable to replicate any genotype-treatment interactions after adjusting for multiple testing. We tested 1 genotype claim on an independent set of data, with negative results. Even if we assumed that interactions in fact did exist, we did not find evidence to support the claim that supplementation leads to a large increase in the risk of advanced AMD in some genotype subgroups. CONCLUSIONS: Patients who meet criteria for supplements to prevent AMD progression should be offered zinc and antioxidants without consideration of genotype.
引用
- Assel MJ, Li F, Wang Y, et al. Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology. 2017. PMID: 29032853. doi:10.1016/j.ophtha.2017.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。